Overall survival among patients with activated phosphoinositide 3-kinase delta syndrome (APDS)
Reduced survival in patients with APDS suggests a high disease burden, particularly in those with concurrent lymphoma. These results highlight the unmet need for disease-modifying treatments for APDS.
Authors
- François Laliberté (ORCID: https://orcid.org/0000-0003-2601-6214)
- Malena Mahendran
- Julia Upton (ORCID: https://orcid.org/0000-0001-5320-4232)
- Katharina Büsch (ORCID: https://orcid.org/0000-0003-4340-7807)
- Heidi L. Memmott
- Guillaume Germain
- Ramya Ramasubramanian
- Amanda Harrington
Institutions
- University of Toronto (CA)
- Hospital for Sick Children (CA)
- Nierstichting (NL)
- Michigan Surgical Hospital (US)
Publication Details
- Journal
- Orphanet Journal of Rare Diseases
- Published
- 2025-05-03
- DOI
- https://doi.org/10.1186/s13023-025-03734-z
- Citations
- 8
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 13.00